<DOC>
	<DOC>NCT00004314</DOC>
	<brief_summary>OBJECTIVES: I. Determine the effects of aminoimidazole carboxamide riboside (AICAR) on hematologic manifestations of Lesch-Nyhan disease. II. Assess the behavioral and neurological benefits of AICAR in patients with Lesch-Nyhan disease. III. Examine the effect of AICAR on purine production.</brief_summary>
	<brief_title>Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE: After a 3-day baseline, patients are treated with aminoimidazole carboxamide riboside (AICAR) by continuous infusion for 12 days. Concurrent allopurinol and folate are allowed.</detailed_description>
	<mesh_term>Lesch-Nyhan Syndrome</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Men with LeschNyhan syndrome Moderate erythrocyte macrocytosis No active urinary tract disease or impaired renal function</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Lesch-Nyhan syndrome</keyword>
	<keyword>inborn errors of metabolism</keyword>
	<keyword>neurologic and psychiatric disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>